The Top 5 Biosimilars Articles for the Week of October 23

Article

The Center for Biosimilars® recaps the top 5 stories in biosimilars news for the week of October 23.

Transcript:

Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of October 23.

Number 5: Novartis credits stronger-than-expected sales of its biosimilars for strong third-quarter net income.

Number 4: Etanercept has been shown to significantly reduce overall healthcare utilization for patients with rheumatoid arthritis, especially for patients who are highly compliant with therapy.

Number 3: New evidence suggests that anti—tumor necrosis factor agents could be repurposed to treat depression that is unresponsive to existing therapies.

Number 2: The FDA has released new educational materials on biosimilars. The resources, geared toward clinicians, include webinars, staff presentations, graphics, and sharable social media assets.

Number 1: The RAND corporation has released a new report on biosimilars, estimating that the United States could save $54 billion over the next 10 years by using biosimilars.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
GBW 2023 webinar
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University,
Fran Gregory, PharmD, MBA
Julie Reed, MS
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Related Content
© 2024 MJH Life Sciences

All rights reserved.